Iterum Therapeutics plc
http://www.iterumtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Iterum Therapeutics plc
US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.
Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Keeping Track: GSK Earns New Claims For Shingrix, Nucala; Keytruda’s TNBC Label Grows; CRL For Iterum
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Biotechnology
- Pharmaceuticals